Blog

Company News

Industry Trends

Laws Regulations

All Categories >

22

2026-06

Hycells HiMag™ Immune Cell Sorting Technology Platform | High Purity, High Viability, Versatile Applications—Redefining the Benchmark for Cell Sorting

With the rapid advancement of cell and gene therapies, the industry is placing increasingly stringent demands on the performance, batch-to-batch consistency, and supply-chain reliability of cell-sorting reagents. At present, the domestic market for sorting magnetic beads remains dominated by imported brands, and their high cost of use and uncertain supply have become significant barriers to both research and industrialization in China.

2026-06-22

He Yousheng

22

2026-06

G4S Antibodies Enable a New Breakthrough in CAR‑T Cell Function Research | Professor Huang He’s Team Publishes in Nature Cancer, Unveiling a Novel Mechanism Regulating Ferroptosis (IF: 28.5) Quality First, Innovation Driven

Recently, Professor Huang He’s team at Zhejiang University published in the top oncology journal “…”. Nature Cancer 》published a research paper titled “Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.” This study is the first to reveal that Serum iron overload By elucidating the key mechanisms by which ferroptosis induces functional exhaustion of CAR‑T cells, we have proposed a targeted approach. ACSL4 Alternatively, a novel strategy involves using the ferroptosis inhibitor Fer-1 to enhance CAR-T cell persistence and antitumor efficacy.

2026-06-22

He Yousheng

22

2026-06

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 2)

HuPBMC model Due to its rapid establishment (3–4 weeks) and ease of use, it has been widely employed for in vivo efficacy evaluation in tumor immunotherapy. However, the conventional model suffers from a critical limitation: the randomness and uncertainty inherent in donor selection. The root of the problem lies not in the model itself, but in the “seed” cells—PBMCs—introduced into the system.

2026-06-22

He Yousheng

22

2026-06

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)

The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.

2026-06-22

He Yousheng

09

2026-06

A Fresh Start, A New Beginning | Hycells’s Brand Identity Fully Reimagined

Every step forward is aimed at fulfilling our mission even more effectively.

2026-06-09

He Yousheng

02

2026-06

Focused on peptide immunogenicity assessment, precisely empowering tumor neoantigens.

In the field of cancer immunotherapy, tumor neoantigen–specific T-cell responses serve as a key metric for assessing peptide immunogenicity. Leveraging its well-established in vitro assay platform, Hycells Biotechnology offers end-to-end services—ranging from initial screening of peptide immunogenicity and antigen‑specific T-cell expansion to validation of tumor cell‑killing activity—thereby supporting the efficient and reliable discovery and validation of neoantigens.

2026-06-02

He Yousheng
< 1234...22 >